Trial Profile
A double-blind, randomised, two-period, crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects of 7 days co-administration of salmeterol (50 mcg bid [twice daily]) with ketoconazole (400 mg od [once daily])
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Salmeterol (Primary) ; Ketoconazole
- Indications Asthma; Mycoses
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 23 May 2007 New trial record.